Hormone breast cancer risk normalizes after stopping pills
Researchers confirmed that a daily, combined dose of estrogen and progestin increases breast cancer risk in post menopausal women, but added that this risk begins to return to normal about six months after women stop taking the hormones. “It is reassuring that breast cancer risk begins to return to normal six months after women stop combined dose estrogen-progestin therapy,” said Duane Alexander, M.D., Director of the NICHD. “Women, in consultation with their physicians, need to make the most informed decision possible. The study authors have provided them with one more piece of important information.”